Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market valsartan tablets, 40 mg, 80 mg, 160 mg and 320 mg. 

Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market valsartan tablets, 40 mg, 80 mg, 160 mg and 320 mg. Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. It is also indicated for the treatment of heart failure. Total annual sales of Valsartan tablets was $1.3 billion as at June 2007.